Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875400 | 1.00 | CXCR4 (0.71) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1874663 | 0.98 | CXCR4 (0.73) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823471 | 0.98 | CXCR4 (0.73) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL3313999 | 0.94 | CXCR4 (0.73) | CXCR4CYP3A4CYP2D6 | |
| Bromide SCHEMBL4543519 | 0.93 | CXCR4 (0.72) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1875171 | 0.92 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823490 | 0.92 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823322 | 0.92 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1877199 | 0.92 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1879283 | 0.92 | CXCR4 (0.68) | CXCR4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4308694-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-115997009-A | Methods and compositions for in vivo transduction of hematopoietic stem and progenitor cells | 美真达治疗公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143302-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO | Magenta Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022197776-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4051298-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |